Percutaneous absorption of progesterone

      Topical progesterone creams and gels have been successfully used for treating menopausal related symptoms and conditions, but their widespread acceptance as standard of care for preventing estrogen-stimulated cell proliferation has been hampered because it results in very little increase in serum progesterone levels. Instead, FDA-approved oral progesterone therapy has remained the mainstay of conventional progesterone therapy for countering estrogen-stimulated proliferation of the endometrium. Venipuncture serum is considered the gold standard for testing sex-steroid hormone levels in the body. It is widely believed that progesterone is poorly absorbed through the skin based on pharmacokinetic studies showing that only about 10% of progesterone delivered topically is detected in serum.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Edelman A.
        • Stouffer R.
        • Zava D.T.
        • Jensen J.T.
        A comparison of blood spot vs. plasma analysis of gonadotropin and ovarian steroid hormone levels in reproductive-age women.
        Fertil Steril. 2007; 88: 1404-1407
        • Du J.Y.
        • Sanchez P.
        • Kim L.
        • Azen C.G.
        • Zava D.T.
        • Stanczyk F.Z.
        Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum whole blood saliva capillary blood.
        Menopause. 2013; 20: 1107-1226
        • Chang K.J.
        • Lee T.T.
        • Linares-Cruz G.
        • Fournier S.
        • de Lignieres B.
        Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo.
        Fertil Steril. 1995; 63: 785-791
        • De Boever J.
        • Verheugen C.
        • Van Maele G.
        • Vandekerckhove D.
        Steroid concentrations in serum, glandular breast tissue, and breast cyst fluid of control and progesterone-treated patients.
        in: Angeli A. Endocrinology of cystic breast disease. Raven Press, New York1983: 93-99
        • Leonetti H.B.
        • Landes J.
        • Steinberg D.
        • Anasti J.N.
        Transdermal progesterone cream as an alternative progestin in hormone therapy.
        Altern Ther Health Med. 2005; 11: 36-38
        • Plu-Bureau G.
        • Le M.G.
        • Thalabard J.C.
        • Sitruk-Ware R.
        • Mauvais-Jarvis P.
        Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease.
        Cancer Detect Prev. 1999; 23: 290-296
        • Sitruk-Ware R.
        • Seradour B.
        • Lafeye C.
        Treatment of benign breast diseases by progesterone applied topically.
        in: Mauvais-Jarvis P. Vickers C.F. Wepierre J. Percutaneous absorption of steroids. Academic Press, London1980: 219-229